SecBot SecBot
PRESS-RELEASE ·Filed Aug 10, 2026

SANA

Sana Biotechnology, Inc
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor for SC451 IND filing and SG293 initial clinical data later this year, as these are the key near-term catalysts. The $160.5M cash position provides runway into mid-2027, but the ATM program may continue to dilute common shareholders. The Mayo Clinic collaboration and $25M investment add credibility to the non-immunosuppressive islet cell approach but do not change the risk profile of a pre-revenue biotech.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.79
T+0 close · Aug 10, 2026 · via day close
Latest settled
−32.45%
T+60 · $2.56
Vs SPY
−31.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $3.79entry
  2. T+1 · 3mo ago −0.53%α −0.78% · $3.77
  3. T+5 · 3mo ago −4.22%α −3.82% · $3.63
  4. T+20 · 2mo ago −16.36%α −15.30% · $3.17
  5. T+60 · 13d ago −32.45%α −31.97% · $2.56
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), slightly narrower than the year-ago $93.8M loss ($0.39/share), driven by the absence of a $44.6M impairment and lower R&D spend. Non-GAAP net loss per share was $0.13, comparing favorably to $0.16 a year ago. The company ended Q2 with $160.5M cash, projecting runway into mid-2027 after raising $93.3M from ATM sales and Mayo Clinic equity investment. Key pipeline catalysts remain on track: SC451 IND/Phase 1/2 start for type 1 diabetes as early as this year, and first-in-human data for SG293 in non-Hodgkin lymphoma also expected this year.

Key Financial Metrics

EPS
−$0.22
Rating
in line

Key Facts

  • Q2 2026 GAAP net loss $63.6M ($0.22/share) vs $93.8M ($0.39/share) in Q2 2025
  • Non-GAAP net loss $39.7M ($0.13/share) vs $38.9M ($0.16/share) a year ago
  • Cash, equivalents, and marketable securities $160.5M as of June 30, 2026; cash runway expected into mid-2027
  • Raised $93.3M in Q2 from ATM sales of common stock and Mayo Clinic equity investment
  • SC451 (iPSC-derived islet cell therapy for type 1 diabetes) IND and Phase 1/2 trial start expected as early as 2026
  • SG293 (CD8-targeted fusosome for non-Hodgkin lymphoma) first-in-human data expected as early as 2026
  • Mayo Clinic invested $25.0M in connection with strategic collaboration for SC451
  • NEJM publication of 14-month UP421 data showing survival and function of HIP-modified islet cells without immunosuppression
  • R&D expenses $30.7M (Q2 2026) vs $29.8M (Q2 2025), up modestly on program advancement
  • Non-cash fair value adjustment on success payments and contingent consideration totaled $23.9M expense in Q2 2026

Financial Impact

No reported revenue; cash burn $69.3M in H1 2026 vs $79.0M in H1 2025; cash position $160.5M with runway to mid-2027 after $93.3M raise

cash burnnet lossR&D spending

Risk Factors

  • Pre-revenue clinical-stage biotech with no approved products; continued operating losses and cash burn
  • SC451 and SG293 are in early/preclinical stages; clinical trial outcomes are highly uncertain
  • ATM equity sales dilute existing shareholders; further dilution likely given cash runway only to mid-2027
  • Contingent consideration and success payment liabilities ($175.3M total) may fluctuate with stock price and program milestones
  • Dependence on contract manufacturers and CDMOs for clinical supply; any manufacturing delays could push back timelines

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3342190

Track record

12 reports on SANA

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
  3. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  4. Aug 10, 202614w ago Press Release Neutral 4/10 Viewing Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
  5. May 11, 202627w ago 8-K Neutral 4/10 No price data
  6. May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  8. Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  9. Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
  10. Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026